Petent and Trademark Critics; U.S. DEPARTMENT OF COMMERC.
Under the Peparteric Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a veild CMS central number.

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

بإلم	{1 i[L	し意	EL	时间
	AUG	1	6	1999	1

In re Application of	
Application Number	Fied
07/998, 114	12/29/92
Group Art Unit Examiner	
	·
	Paper No. 12

Assistant Commissioner for Patents Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the identified ABANDONED application, which is: (CHECK ON	(E)
(A) referred to in United States Patent Number 5.	674,882 column
(B) referred to in an application that is open to public Application No, filed,	Inspection as set forth in 37 CFR 1.11, i.e., on page of
(C) an application that claims the benefit of the filing to inspection, i.e., Application No.	date of an application that is open to public filed, or
(D) an application in which the applicant has filed an application to the public.	authorization to lay open the complete
Please direct any correspondence concerning this reque	st to the following address:
Mat Pany	8/16/99 Date
Mathaniel Parry	
Typed or printed name	Approved by:
	(Infilais)

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individuance. Any commence on the amount of time you are required to complete this form should be sent to the Chief Internation Office. Page and Trademark Office. Washington. DC 20231. DC NOT DEND FEES OR COMPLETED FORMS TO THIS ADDRESS. 384.3.03. Assument: Commissioner for Palents. Washington.

[11] Parent Number:

[45]

Date of Patent:

5,674,882 Oct. 7, 1997

[54] RETROVIRAL PROTEASE INHIBITING COMPOUNDS

[75] Inventors: Dale J. Kempf, Libertyville; Daniel W. Norbeck, Crystal Lake; Hing Leung Sham; Chen Zhao, both of Gurnee, all

of III.

[73] Assignee: Abbott Laboratories, Abbott Park, Ill.

[21] Appl. No.: 413,136

[22] Filed: Mar. 29, 1996

Related U.S. Application Data

[60] Division of Ser. No. 158,587, Dec. 2, 1993, shandoned, which is a continuation-in-part of Ser. No. 998,114, Dec. 29, 1992, shandoned, which is a continuation-in-part of Ser. No. 777,626, Oct. 23, 1991, which is a continuation-in-part of Ser. No. 746,020, Aug. 15, 1991, shandoned, which is a continuation-in-part of Ser. No. 616,170, Nov. 20, 1990, shandoned, which is a continuation-in-part of Ser. No. 5,142,036, which is a continuation-in-part of Ser. No. 456,124, Dec. 22, 1969, shandoned, which is a continuation-in-part of Ser. No. 403,674, Sep. 8, 1969, shandoned, which is a continuation-in-part of Ser. No. 353,945, May 23, 1969, shandoned.

[51]	Int. C	L	***************************************	 AGIK 31/41
[52]	U.S. C			

[58] Floid of Search 514/365,

[56] References Cited U.S. PATENT DOCUMENTS

4 177 094	10/1979	Dybas ot al	544/396
4 618 619	10/1986	Regel et al	514/383
		Kettner et al	
		Kettner et al.	
3,142,000	M1337	Kempf et al	34656
5,354,800	10/1974	Kempf et al	340/203

Primary Examiner—Russell Travers
Attorney, Agent, or Firm—Steven R. Crowley

[57] ABSTRACT

A retroviral protesse inhibiting compound of the formula:

is disclosed.

3 Claims, No Drawings